Source: Pfizer
Area: News
Pfizer has issued a communication about a potential for injecting an excess volume of pegaptanib sodium (Macugen®) intravitreally. This risk has been identified in a clinical trial and in clinical practice. Two cases have been reported in which a volume of Macugen greater than the recommended volume (90 ?L) was injected into a patient's eye with a subsequent elevation of intraocular pressure (lOP). In both cases, the lOP became elevated to a level which required anterior chamber paracentesis.
The Company advises that to ensure the safe administration of Macugen intravitreally, the excess product volume should be expelled by slowly depressing the plunger so that the top edge of the 3rd rib on the plunger stopper aligns with the pre-printed black dosing line.
The Summary of Product Characteristics, the patient leaflet and the packaging material have been updated. In particular, the administration instructions of Macugen injection have been enhanced and ...
Uncategorized